Novo Nordisk ADR [NYSE: NVO] surged by $2.32 during the normal trading session on Friday and reaching a high of $51.3 during the day while it closed the day at $51.08.
Novo Nordisk ADR stock has also gained 6.00% of its value over the past 7 days. However, NVO stock has declined by -21.23% in the 3 months of the year. Over the past six months meanwhile, it has lost -41.40% and lost -60.74% year-on date.
The market cap for NVO stock reached $171.94 billion, with 3.37 billion shares outstanding and 3.37 billion shares in the current float. Compared to the average trading volume of 14.10M shares, NVO reached a trading volume of 23125499 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Novo Nordisk ADR [NVO]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for NVO shares is $75.77 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on NVO stock is a recommendation set at 2.25. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
UBS have made an estimate for Novo Nordisk ADR shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on August 05, 2025. The new note on the price target was released on July 31, 2025, representing the official price target for Novo Nordisk ADR stock.
The Price to Book ratio for the last quarter was 8.58, with the Price to Cash per share for the same quarter was set at 0.88. Price to Free Cash Flow for NVO in the course of the last twelve months was 18.12 with Quick ratio for the last quarter at 0.56.
NVO stock trade performance evaluation
Novo Nordisk ADR [NVO] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 6.00. With this latest performance, NVO shares dropped by -28.07% in over the last four-week period, additionally sinking by -41.40% over the last 6 months – not to mention a drop of -40.62% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for NVO stock in for the last two-week period is set at 36.04, with the RSI for the last a single of trading hit 2.91, and the three-weeks RSI is set at 2.69 for Novo Nordisk ADR [NVO]. The present Moving Average for the last 50 days of trading for this stock 67.09, while it was recorded at 48.25 for the last single week of trading, and 80.96 for the last 200 days.
Novo Nordisk ADR [NVO]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Novo Nordisk ADR [NVO] shares currently have an operating margin of 46.36% and a Gross Margin at 83.94%. Novo Nordisk ADR’s Net Margin is presently recorded at 35.60%.
Novo Nordisk ADR (NVO) Capital Structure & Debt Analysis
According to recent financial data for Novo Nordisk ADR. ( NVO), the Return on Equity (ROE) stands at 75.95%, highlighting impressive shareholder gains. The Return on Assets (ROA) is 25.10%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Novo Nordisk ADR’s Return on Invested Capital (ROIC) is 40.28%, showcasing its effectiveness in deploying capital for earnings.
Novo Nordisk ADR (NVO) Efficiency & Liquidity Metrics
Based on Novo Nordisk ADR’s (NVO) latest financial statements, the Debt-to-Equity Ratio is 0.59%, indicating its reliance on debt financing relative to shareholder equity.
Novo Nordisk ADR (NVO) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Novo Nordisk ADR. (NVO) effectively leverages its workforce, generating an average of $212052.11 per employee. The company’s liquidity position is robust, with a Current Ratio of 0.78% and a Quick Ratio of 0.56%, indicating strong ability to cover short-term liabilities.
Earnings per share (EPS) analysis for Novo Nordisk ADR [NVO] stock
With the latest financial reports released by the company, Novo Nordisk ADR posted 6.12/share EPS, while the average EPS was predicted by analysts to be reported at 5.92/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 0.2. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for NVO. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Novo Nordisk ADR go to 14.16%.
Novo Nordisk ADR [NVO]: Institutional Ownership
There are presently around $9.82%, or 9.82%% of NVO stock, in the hands of institutional investors. The top three institutional holders of NVO stocks are: JENNISON ASSOCIATES LLC with ownership of 21.22 million shares, which is approximately 0.476%. FMR LLC, holding 19.49 million shares of the stock with an approximate value of $$2.78 billion in NVO stocks shares; and FMR LLC, currently with $$2.09 billion in NVO stock with ownership which is approximately 0.3272%.
